17 Piot, Ines Schweyer, Kerstin Respondek, Gesine Stamelou, Maria group, DescribePSP study group, ProPSP study group, MDS-endorsed PSP study Sckopke, Philipp Schenk, Thomas Goetz, Christopher G Stebbins, Glenn T Höglinger, Günter Gasser, Thomas Hermann, Andreas Höglinger, Günter Höllerhage, Matthias Kimmich, Okka Klockgether, Thomas Levin, Johannes Machetanz, Gerrit Osterrath, Antje Palleis, Carla Prudlo, Johannes Spottke, Annika Berg, Daniela Bürk, Katrin Claßen, Joseph Eggers, Carsten Greuel, Andrea Grimm, Max-Joseph Hermann, Lennard Iankova, Vassilena Jahn, Klaus Jost, Wolfgang Klietz, Martin Kühn, Andrea Marxreiter, Franz Paschen, Steffen Poetter-Nerger, Monika Preisl, Marie-Therese Prilop, Lisa Tönges, Lars Trenkwalder, Claudia Warnecke, Tobias Wegner, Florian Winkler, Jürgen Antonini, Angelo P, Kailash P L, Adam L Colosimo, Carlo Compta, Yaroslau Corvol, Jean-Christophe I, Lawrence I Höglinger, Günter U E, Anthony E Litvan, Irene R, Huw R Nilsson, Christer Pantelyat, Alexander Respondek, Gesine Stamelou, Maria AG Höglinger Movement disorders Movement disorders Wiley New York, NY 0885-3185 10.1002/mds.27964 English 650-661 4 35 There is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.To develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.The Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).Cognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P < 0.001). Individual Progressive Supranuclear Palsy Clinical Deficits Scale items correlated well with similar constructs in existing scales. Internal consistency (Cronbach's alpha: 0.75), inter-rater reliability (0.96), and test-retest stability (0.99) were acceptable. The PSP-CDS showed significant 12-month change (baseline, 8.6 ± 3.6; follow-up: 10.8 ± 3.6; annualized difference: 3.4 ± 3.4; n = 49; P < 0.0001). Sample sizes required per arm for a two-arm, 1-year follow-up therapeutic trial to detect 50% change in Progressive Supranuclear Palsy Clinical Deficits Scale progression was estimated to be 65 (two-sided, two-sample t test).The Progressive Supranuclear Palsy Clinical Deficits Scale is a rapidly completed, clinimetrically sound scale for clinical care and research involving PSP. © 2020 International Parkinson and Movement Disorder Society. PUB:(DE-HGF)16, ; 0, ; Disease Progression Female Fingers Humans Male Motor Skills Reproducibility of Results Supranuclear Palsy, Progressive: diagnosis Journal Article 2020 DZNE-2020-00406 2020 pmid:31951049 https://pub.dzne.de/record/145046 https://doi.org/10.1002/mds.27964